Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term observational study of certolizumab pegol in rheumatoid arthritis
NL-OMON20435Phase 4Recruiting
- Sponsor
- Jan van Breemen Institute
- Start
- Mar 2011
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of certolizumab pegol in rheumatoid arthritis (RA), sponsored by Jan van Breemen Institute. Primary endpoints: Efficacy versus baseline, Radiological progression and 3 more. Started Mar 2011; status: recruiting.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON20435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20435.